Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report

被引：0
|
作者：
Ali, Elrazi A. [1 ]
Jain, Monika [1 ]
Pokhrel, Akriti [2 ]
Mooppan, Unni [3 ]
Wang, Jen chin [2 ]
机构：
[1] One Brooklyn Hlth, Interfaith Med Ctr, Internal Med Dept, Brooklyn, NY USA
[2] One Brooklyn Hlth, Brookdale Univ Hosp, Med Ctr, Dept Hematol & Med Oncol, Brooklyn, NY 11213 USA
[3] One Brooklyn Hlth, Brookdale Univ Hosp, Med Ctr, Dept Urol, Brooklyn, NY 11212 USA
来源：
LEUKEMIA RESEARCH REPORTS | 2024年 / 22卷
关键词：
Aplastic anemia; Olaparib; Prostate cancer; Pancytopenia; ACUTE MYELOID-LEUKEMIA;
D O I：
10.1016/j.lrr.2024.100473
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Olaparib is (ADP-ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate cancer (CRPC), there have been some reports of myelodysplastic syndrome (MDS) and acute leukemia linked to PARP inhibitor use for ovarian, breast, pancreatic and breast cancers, there have been no reports of aplastic anemia after receiving PARPi therapy. This case report describes a 75-year-old man with BRCA2-positive metastatic castrate-resistant prostate cancer who developed aplastic anemia after taking olaparib.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Antithymocyte globulin for aplastic anemia secondary to pembrolizumab: a case report and review of literature
    Yeung, Cynthia
    Relke, Nicole
    Good, David
    Satkunam, Natasha
    Mates, Mihaela
    IMMUNOTHERAPY, 2023, 15 (05) : 323 - 333
  • [42] Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
    Rouvinov, Keren
    Nalbandyan, Karen
    Kozlov, Victor
    Peled, Nir
    Yakobson, Alexander
    CASE REPORTS IN ONCOLOGY, 2019, 12 (01): : 29 - 32
  • [43] Aplastic anemia complicating systemic lupus erythematosus - report of a case and review of the literature
    Pavithran, K
    Raji, NL
    Thomas, M
    RHEUMATOLOGY INTERNATIONAL, 2002, 22 (06) : 253 - 255
  • [44] The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective
    Yanada, Brendan A.
    Homewood, David
    Dias, Brendan H.
    Ogluszko, Cindy
    Corcoran, Niall M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (06) : 175.e9 - 175.e18
  • [45] Colon cancer in a patient with underlying aplastic anemia: A clinical challenge
    Wong, Hilda
    Chan, Pierre
    Yau, Thomas
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2012, 3 (02): : 29 - 31
  • [46] Potential role of rituximab in metastatic castrate-resistant prostate cancer
    Bindal, Poorva
    Jalil, Sharif A. A.
    Holle, Lisa M.
    Clement, Jessica M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1509 - 1511
  • [47] Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change
    Dediu, Mircea
    Bratu, Florentina
    Amarandei, Mihaela
    Fejer, Eniko
    JOURNAL OF BUON, 2016, 21 (06): : 1379 - 1382
  • [48] Next Generation Sequencing in metastatic castrate-resistant prostate cancer
    Adashek, Jacob J.
    Salgia, Meghan
    Pal, Sumanta K.
    UROLOGY CASE REPORTS, 2018, 19 : 60 - 62
  • [49] Recomendations on the Management of Controversies in Advanced Castrate-Resistant Prostate Cancer
    Cozar, J. M.
    Solsona, E.
    Morote, J.
    Minana, B.
    Maroto, J. P.
    Gonzalez del Alba, A.
    Climent, M. A.
    Carles, J.
    Alcaraz, A.
    Castellano, D.
    ACTAS UROLOGICAS ESPANOLAS, 2012, 36 (10): : 569 - 577
  • [50] Current state of theranostics in metastatic castrate-resistant prostate cancer
    Nindra, Udit
    Lin, Peter
    Becker, Therese
    Roberts, Tara L.
    Chua, Wei
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2024, 68 (04) : 412 - 420
12345